Panorama Medicine combines genomics and computing to develop RNA-targeted therapeutics through a screening and big-data discovery platform. It leverages core technologies licensed from academic partners to identify drugs that address diseases caused by errors in RNA processing. The company was launched in 2018 by Dr. Yi Xing, Dr. Douglas Black, and Mingfu Zhu (CEO). Panorama plans to expand its scientific team, continue advancing its screening and big-data discovery platform, and progress its drug development efforts. The company recently added Dr. Beverly Davidson to its Scientific Advisory Board; she holds leadership and advisory roles across multiple gene and cell therapy organizations. Panorama is based in Philadelphia, PA.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2019